[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 323
Citations 0
Correction
June 20, 2019

Errors in Data Presentation in Text, Figures, Table, and eTables

JAMA Oncol. 2019;5(8):1232. doi:10.1001/jamaoncol.2019.2422

In the Original Investigation by Hilal et al titled “Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration” published online May 2, 2019, in JAMA Oncology,1 there were errors in the number of US Food and Drug Administration approvals and trials described in the Abstract; Results, Discussion, and Conclusions sections; Figures; Table, and eTables. In Figure 1, 48 anticancer drug approvals were excluded, 95 drug approvals were reviewed, and 79 approvals were based on randomized clinical trials with optimal controls. The suboptimal control bars for genitourinary and lung/head and neck tumors in Figure 2 should reach 4% and 2%, respectively. In the Table, the study by Hussain et al has been added and the study by Kim et al has been deleted. In Supplement 2, the PROSPER trial was deleted from eTable 1 and added to eTable 2. The ALTA trial was deleted from eTable 2. This article was corrected online.

References
1.
Hilal  T, Sonbol  MB, Prasad  V.  Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration  [published online May 2, 2019].  JAMA Oncol. doi:10.1001/jamaoncol.2019.0167PubMedGoogle Scholar
×